©The Author(s) 2025.
World J Gastrointest Pharmacol Ther. Dec 5, 2025; 16(4): 110273
Published online Dec 5, 2025. doi: 10.4292/wjgpt.v16.i4.110273
Published online Dec 5, 2025. doi: 10.4292/wjgpt.v16.i4.110273
Table 1 Baseline demographics of the study population
| Characteristics | n (%) |
| Sex | |
| Male | 27 (52.9) |
| Female | 24 (47.1) |
| Montreal disease classification | |
| Age at diagnosis | |
| A1 | 7 (13.7) |
| A2 | 25 (49) |
| A3 | 19 (37.3) |
| Location | |
| L1-ileal | 19 (37.3) |
| L2-colonic | 10 (19.6) |
| L3-ileocolonic | 21 (41.2) |
| L4-isolated upper gi disease | 1 (1.9) |
| Behaviour | |
| B1-non-stricturing | 22 (43.1) |
| B2-stricturing | 18 (35.3) |
| B2/3-stricturing and penetrating | 5 (9.8) |
| B3-penetrating | 6 (11.7) |
| Perianal disease | 7 (13.7) |
| Number of previous advanced therapies | |
| 1 | 7 (13.7) |
| 2 | 32 (62.8) |
| 3 | 9 (17.6) |
| 4 | 3 (5.9) |
- Citation: Colwill M, Padley J, Qazi U, Mehta S, Donovan F, Alves AM, Pollok R, Patel K, Dawson P, Honap S, Poullis A. Risankizumab is effective following ustekinumab failure in Crohn’s disease: A real-world study from a tertiary center. World J Gastrointest Pharmacol Ther 2025; 16(4): 110273
- URL: https://www.wjgnet.com/2150-5349/full/v16/i4/110273.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v16.i4.110273